DUBLIN, June 4, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/jwzdfx/psoriasis) has announced the addition of the "Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion.
This report provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by a team of industry experts.
The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results.
However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein.
It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.
Key Topics Covered:
1 Tables & Figures
3 Marketed Products
4 Psoriasis Market to 2021 - Pipeline Products
5 Market Forecast to 2021
6 Deals and Strategic Consolidations
- 4SC Discovery
- Cipher Pharmaceuticals
- Dr. Reddy's Laboratories
- Eli Lilly
- IBSA Institut Biochimique
- Janssen Biotech
- LEO Pharma
- Leo Pharma
- Phenex Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/jwzdfx/psoriasis
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets